Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Evaluation of anti-tumour activities of the novel small molecule PRIMA-1met in Waldenstrom Macroglobulinemia

FY 2013-14

Summary
Waldenstrom macroglobulinemia (WM) is a cancer of terminally differentiated B-cells, ie. plasma cells, which play major roles in white blood cells immunity. The faith of WM patients is very heterogeneous but the 5 year survival rate is reported to be 50%.1 Current medications used for WM patients are not highly effective and the chances of reoccurrence are great. Therefore, finding an alternative treatment is a priority for people working in this area. PRIMA-1met is a drug which has shown promising results in phase I/II clinical trials in patients with hematological and prostate cancer.2 This drug is a small molecule agent that restores the wild type conformation of mutant P53. P53, a tumor suppressor, in turn plays a major role in causing cell death in cancer cells. Therefore, targeting P53 with small molecules such as PRIMA-1met can be an attractive therapeutic strategy. My research will focus on laying the preclinical ground work needed for further evaluation of PRIMA-1met as a novel therapeutic approach for the treatment of WM patients. I will investigate the cell viability and the changes in the internal protein network of the WM cells after administrating PRIMA-1met in order to examine its level of cytotoxicity and effectivity in killing WM cancer cells and elucidate the cellular pathways this drug affects. References: 1. Dhodapkar MV, Hoering A, Gertz MA et al.(2009). Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Blood 113(4):793-6. 2. Lehmann S., Bykov V.J., Ali D. et al. (2012). Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol.30(29):3633-9.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311749
Name
Sobhani Mona
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation of anti-tumour activities of the novel small molecule PRIMA-1met in Waldenstrom Macroglobulinemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Cancer Drug; Apoptosis; Lymphoplasmacytic Lymphoma; P53; Prima-1met; Small Molecule Drugs; Waldenstrom Macroglobulinemia
Abstract
Waldenstrom macroglobulinemia (WM) is a cancer of terminally differentiated B-cells, ie. plasma cells, which play major roles in white blood cells immunity. The faith of WM patients is very heterogeneous but the 5 year survival rate is reported to be 50%.1 Current medications used for WM patients are not highly effective and the chances of reoccurrence are great. Therefore, finding an alternative treatment is a priority for people working in this area. PRIMA-1met is a drug which has shown promising results in phase I/II clinical trials in patients with hematological and prostate cancer.2 This drug is a small molecule agent that restores the wild type conformation of mutant P53. P53, a tumor suppressor, in turn plays a major role in causing cell death in cancer cells. Therefore, targeting P53 with small molecules such as PRIMA-1met can be an attractive therapeutic strategy. My research will focus on laying the preclinical ground work needed for further evaluation of PRIMA-1met as a novel therapeutic approach for the treatment of WM patients. I will investigate the cell viability and the changes in the internal protein network of the WM cells after administrating PRIMA-1met in order to examine its level of cytotoxicity and effectivity in killing WM cancer cells and elucidate the cellular pathways this drug affects. References: 1. Dhodapkar MV, Hoering A, Gertz MA et al.(2009). Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Blood 113(4):793-6. 2. Lehmann S., Bykov V.J., Ali D. et al. (2012). Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol.30(29):3633-9.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sobhani, Mona
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~